Literature DB >> 3748896

Design of cytotoxic steroids for prostate cancer.

V Petrow, G M Padilla.   

Abstract

Our object was to determine if the aromatic nucleus of estramustine (I) is optimal for binding affinity to prostate cytosolic proteins, and if C3 is the preferred position for the N-mustard carbamate moiety. To this end we have submitted 34 steroids for in vitro assay of binding affinity to total prostate cytosolic proteins. Our structures included aromatic and hydroaromatic steroids containing N-mustard carbamate and other substituents at C3, C6, C11, C16, C17, C20, and C21. Our results show that binding affinity to prostate proteins is optimally present in C3-nitrogen mustard carbamates attached directly to a totally planar aromatic ring as in (IV). Partial deviation from total planarity as in enol-carbamates (V) leads to some loss of binding affinity, which largely disappears in hydroaromatic structures (VI). Thus, our data lead to the Ring A aromatic structure (X) as a basis for the design of steroidal N-mustard carbamates with prostate selectivity. Preliminary in vivo studies using the Dunning R3327AT prostatic adenocarcinoma implanted in the Copenhagen rat generally support our in vitro data.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3748896     DOI: 10.1002/pros.2990090207

Source DB:  PubMed          Journal:  Prostate        ISSN: 0270-4137            Impact factor:   4.104


  2 in total

1.  Accumulation of estramustine and estromustine in adipose tissue of rats and humans.

Authors:  P O Gunnarsson; S B Andersson; A A Sandberg; M Ellman
Journal:  Cancer Chemother Pharmacol       Date:  1991       Impact factor: 3.333

2.  Transition metal-catalysed A-ring C-H activations and C(sp2)-C(sp2) couplings in the 13α-oestrone series and in vitro evaluation of antiproliferative properties.

Authors:  Péter Traj; Ali Hazhmat Abdolkhaliq; Anett Németh; Sámuel Trisztán Dajcs; Ferenc Tömösi; Tea Lanisnik-Rizner; István Zupkó; Erzsébet Mernyák
Journal:  J Enzyme Inhib Med Chem       Date:  2021-12       Impact factor: 5.051

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.